$FBIOP News
Last published 2mo ago
- 2mo agoFBIOFBIOPFortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for
- 3mo agoFBIOFBIOPFortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B
- 3mo agoFBIOFBIOPFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B FinancingGlobeNewswireMIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys
- 5mo agoFBIOFBIOPFortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare ConferenceGlobeNewswireMIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
- 6mo agoFBIOFBIOPFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress'
- 6mo agoFBIOFBIOPFortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceGlobeNewswireMIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
- 7mo agoFBIOFBIOPFortress Biotech Reports 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million;
- 7mo agoFBIOFBIOPFortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewswireMIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of
- 8mo agoFBIOFBIOPUPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewswireMIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a
- 8mo agoFBIOFBIOPFortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewswireMIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a
- 10mo agoFBIOFBIOPFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United StatesGlobeNewswireRare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate
- 11mo agoFBIOFBIOPFortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA ResubmissionGlobeNewswireMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug
- 12mo agoFBIOFBIOPFortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at
- 1y agoFBIOFBIOPFortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of GoutGlobeNewswireMIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc.
- 1y agoFBIOFBIOPFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A FinancingGlobeNewswireDotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3%
- 1y agoFBIOFBIOPFortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101GlobeNewswireMIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug
- 1y agoFBIOFBIOPFortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
- 1y agoFBIOFBIOPFortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5%
- 1y agoFBIOFBIOPFortress Biotech Announces Closing of Sale of Subsidiary Checkpoint TherapeuticsGlobeNewswireMIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint
- 1y agoFBIOFBIOPFortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceGlobeNewswireMIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint
- 1y agoFBIOFBIOPPartex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI PlatformGlobeNewswireFRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company, today announced a strategic collaboration aimed
- 1y agoFBIOFBIOPFortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCTGlobeNewswireStudy is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the benefit of vaccinating
- 1y agoFBIOFBIOPFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes DiseaseGlobeNewswirePriority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous
- 2y agoFBIOFBIOPFortress Biotech to Participate in October 2024 Investor ConferencesGlobeNewswireMIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
- 2y agoFBIOFBIOPFortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
- 2y agoATXICKPTDERMFBIO+1Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswirePDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or
- 2y agoFBIOFBIOPFortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027GlobeNewswireMIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress", or the "Company"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value
- 2y agoFBIOFBIOPFortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred StockGlobeNewswireMIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO, FBIOP)) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for
- 4y agoFBIOFBIOPFortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred StockGlobeNewswireMIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (NASDAQ:FBIOP) ("Fortress"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic prod
- 6y agoFBIOFBIOPFortress Biotech Announces Pricing of Series A Preferred Stock OfferingGlobeNewswireNEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today...
- 6y agoFBIOFBIOPFortress Biotech Announces Pricing of Series A Preferred Stock OfferingGlobeNewswireNEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced...
- 6y agoFBIOFBIOPFortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate HighlightsGlobeNewswireFirst quarter 2020 product revenue increased 95% year-over-year to $11.9 million NDA for IV tramadol accepted for review by FDA; assigned PDUFA date of October 10, 2020 Agreement executed with...
- 6y agoFBIOFBIOPFortress Biotech Announces Pricing of Series A Preferred Stock OfferingGlobeNewswireNEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on...
- 6y agoFBIOFBIOPFortress Biotech Announces Pricing of Series A Preferred Stock OfferingGlobeNewswireNEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on...